2023
JS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. JS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL. Neuro-Oncology 2023, 25: ii12-ii13. PMCID: PMC10489492, DOI: 10.1093/neuonc/noad137.034.Peer-Reviewed Original ResearchRecurrent brain metastasesImage interpretation criteriaBrain metastasesRadiation therapyLesion uptakeDiagnostic performancePredictive valueProspective phase 2 trialSolid tumor brain metastasesTumor brain metastasesPhase 2 trialInterpretation criteriaNegative predictive valueLow background uptakePositive predictive valueExcellent diagnostic performanceBM recurrencePost-MRIPrimary endpointSecondary endpointsRadiation necrosisReference lesionsUnnecessary surgeryHistopathological analysisInitial cohortNEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR18F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. NEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR18F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY. Neuro-Oncology Advances 2023, 5: iii15-iii15. PMCID: PMC10402431, DOI: 10.1093/noajnl/vdad070.057.Peer-Reviewed Original ResearchEvaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. Journal Of Clinical Oncology 2023, 41: 2001-2001. DOI: 10.1200/jco.2023.41.16_suppl.2001.Peer-Reviewed Original ResearchRecurrent brain metastasesImage interpretation criteriaF-fluciclovine PETF-fluciclovine uptakeBrain metastasesF-fluciclovineRadiation therapyDiagnostic performanceHistopathological analysisSUV maxFirst prospective multicenter trialProspective phase 2 trialSolid tumor brain metastasesTumor brain metastasesPhase 2 trialProspective multicenter trialIndependent blinded readersFluciclovine uptakePost-MRIPrimary endpointSecondary endpointsMulticenter trialRadiation necrosisRecurrent tumorsFuture trials
2022
NIMG-02. PACS-INTEGRATED AUTO-SEGMENTATION WORKFLOW FOR BRAIN METASTASES USING NNU-NET
Jekel L, Bousabarah K, Lin M, Merkaj S, Kaur M, Avesta A, Aneja S, Omuro A, Chiang V, Scheffler B, Aboian M. NIMG-02. PACS-INTEGRATED AUTO-SEGMENTATION WORKFLOW FOR BRAIN METASTASES USING NNU-NET. Neuro-Oncology 2022, 24: vii162-vii162. PMCID: PMC9661012, DOI: 10.1093/neuonc/noac209.622.Peer-Reviewed Original Research
2021
Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report
Lu BY, Isitan C, Mahajan A, Chiang V, Huttner A, Mitzner JR, Wesley SF, Goldberg SB. Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report. JTO Clinical And Research Reports 2021, 2: 100183. PMID: 34590030, PMCID: PMC8474265, DOI: 10.1016/j.jtocrr.2021.100183.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMultiple sclerosisRadiation necrosisBrain lesionsWhole-brain radiation therapyImmune checkpoint therapyViable tumor cellsPaucity of dataBrain metastasesCheckpoint inhibitorsMetastatic NSCLCAdverse eventsCheckpoint therapyDurable responsesNeurologic declineRadiographic benefitIntracranial complicationsPathologic findingsAutoimmune disordersAutoimmune diseasesCase reportIntracranial diseaseRadiation therapyStereotactic radiosurgeryAnticancer benefits
2019
Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience
Hughes RT, Masters AH, McTyre ER, Farris MK, Chung C, Page BR, Kleinberg LR, Hepel J, Contessa JN, Chiang V, Ruiz J, Watabe K, Su J, Fiveash JB, Braunstein S, Chao S, Attia A, Ayala-Peacock DN, Chan MD. Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2019, 104: 1091-1098. PMID: 30959122, DOI: 10.1016/j.ijrobp.2019.03.052.Peer-Reviewed Original ResearchConceptsDistant brain failureInitial stereotactic radiosurgerySalvage whole brain radiation therapyWhole-brain radiation therapySalvage stereotactic radiosurgeryBrain metastasesBrain radiation therapyOverall survivalStereotactic radiosurgeryBM groupCumulative incidenceRadiation therapyNumber of BMTwo-year cumulative incidenceMultivariable Cox proportional hazardsBrain metastasis velocityMedian overall survivalOutcomes of patientsKaplan-Meier methodLog-rank testMulti-institutional experienceRisk regression modelingCox proportional hazardsMultivariable analysisNew metastases
2017
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: 1069-1077. PMID: 28721890, PMCID: PMC6925531, DOI: 10.1016/j.ijrobp.2017.03.030.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBrain NeoplasmsFemaleGenes, rasHumansImmunotherapyLinear ModelsMaleMelanomaMiddle AgedMolecular Targeted TherapyMutationPrognosisProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitRetrospective StudiesStatistics, NonparametricTime FactorsConceptsBRAF-negative patientsBRAF-positive patientsBrain metastasesMedian survivalC-kit mutationsMelanoma patientsPrimary diagnosisWhole-brain radiation therapyOverall median survivalMulti-institutional databaseGene mutation statusOverall survivalInitial treatmentMedian timeTreatment patternsClinical parametersBRAF statusPrognostic valueNRAS mutationsRadiation therapyPatientsMutation statusMetastasisC-kitMEK inhibitors
2016
Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
Lester-Coll NH, Dosoretz AP, Magnuson WJ, Laurans MS, Chiang VL, Yu JB. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases. Journal Of Neurosurgery 2016, 125: 18-25. PMID: 27903191, DOI: 10.3171/2016.7.gks161499.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyIncremental cost-effectiveness ratioQuality-adjusted life yearsBrain metastasesStereotactic radiosurgeryProbabilistic sensitivity analysesJLGK0901 studyRadiation therapyEffective treatment optionMethods A Markov modelCost-effectiveness ratioHealth state utilitiesCost-effective relativeStandard gamble methodA Markov modelRecurrence ratePatient preferencesTreatment optionsPatientsMetastasisLife yearsEuropean OrganizationPay thresholdsEnd pointCost-effective strategyDeferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis
Magnuson W, Amini A, Patil T, Kavanagh B, Camidge D, Braunstein S, Boreta L, Attia A, Rana N, Contessa J, Gettinger S, Lester-Coll N, Yu J, Chiang V. Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s57-s58. DOI: 10.1016/j.ijrobp.2016.06.149.Peer-Reviewed Original ResearchImpact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2016, 95: 673-679. PMID: 27034176, DOI: 10.1016/j.ijrobp.2016.01.037.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyUpfront EGFR-TKIIntracranial progression-free survivalUpfront radiation therapyProgression-free survivalBrain metastasesEGFR-TKI groupEGFR-TKIEGFR-mutant NSCLCOverall survivalRadiation therapyEpidermal Growth Factor Receptor–Mutant NonDisease-specific Graded Prognostic AssessmentUpfront EGFR tyrosine kinase inhibitorsEGFR-TKI resistance mutationSmall cell lung cancerEGFR tyrosine kinase inhibitorsEGFR-TKI useMedian overall survivalSimilar overall survivalUpfront RT groupInferior overall survivalCell lung cancerMutant lung adenocarcinomaEpidermal growth factor receptorPractice Building: Achieving Growth Through Computed Tomographic Myelography–Based Stereotactic Body Radiation Therapy for Spinal Metastases
Zohrabian VM, Husain ZA, Laurans MS, Chiang VL, Mahajan A, Johnson MH. Practice Building: Achieving Growth Through Computed Tomographic Myelography–Based Stereotactic Body Radiation Therapy for Spinal Metastases. Current Problems In Diagnostic Radiology 2016, 45: 324-329. PMID: 26920633, DOI: 10.1067/j.cpradiol.2016.01.004.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyBody radiation therapySpinal metastasesTomographic myelographyRadiation therapyWorkup of patientsStereotactic radiation treatmentMultidisciplinary careNeural elementsSBRT programRadiation treatmentMyelographyMetastasisPatientsTherapyRadiologistsMagnetic resonanceStandardized methodCeritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer
Qian J, Yu J, Gettinger S, Chiang V. Ceritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer. Cancer Treatment And Research Communications 2016, 6: 17-19. DOI: 10.1016/j.ctrc.2016.02.002.Peer-Reviewed Original ResearchNon-small cell lung cancerAnaplastic lymphoma kinaseWhole-brain radiation therapySymptomatic brain metastasesBrain radiation therapyCell lung cancerBrain metastasesStereotactic radiosurgerySystemic therapyLung cancerRadiation therapyActive small-molecule tyrosine kinase inhibitorLarge symptomatic brain metastasisNext-generation ALK inhibitorsSmall molecule tyrosine kinase inhibitorsYear old Caucasian femaleMolecule tyrosine kinase inhibitorsGeneration ALK inhibitorsALK inhibitor crizotinibOld Caucasian femaleKey driver mutationsTyrosine kinase inhibitorsLocal therapyInhibitor crizotinibALK inhibitors
2015
Gamma Knife radiosurgery for posterior fossa meningiomas: a multicenter study.
Sheehan JP, Starke RM, Kano H, Barnett GH, Mathieu D, Chiang V, Yu JB, Hess J, McBride HL, Honea N, Nakaji P, Lee JY, Rahmathulla G, Evanoff WA, Alonso-Basanta M, Lunsford LD. Gamma Knife radiosurgery for posterior fossa meningiomas: a multicenter study. Journal Of Neurosurgery 2015, 122: 1479-89. PMID: 25859812, DOI: 10.3171/2014.10.jns14139.Peer-Reviewed Original ResearchConceptsPosterior fossa meningiomasTumor volumeStereotactic radiosurgeryTumor controlRadiation therapyNorth American Gamma Knife ConsortiumTumor progressionActuarial tumor controlMedian margin doseMedian patient agePrior radiation therapyMean tumor volumeGamma knife radiosurgerySmaller tumor volumeNeurological preservationMargin dosePrior resectionClinical stabilityNeurological declinePatient ageShunt placementRecurrent tumorsClinical entityMulticenter studyKnife radiosurgery
2014
Gamma Knife radiosurgery for sellar and parasellar meningiomas: a multicenter study.
Sheehan JP, Starke RM, Kano H, Kaufmann AM, Mathieu D, Zeiler FA, West M, Chao ST, Varma G, Chiang VL, Yu JB, McBride HL, Nakaji P, Youssef E, Honea N, Rush S, Kondziolka D, Lee JY, Bailey RL, Kunwar S, Petti P, Lunsford LD. Gamma Knife radiosurgery for sellar and parasellar meningiomas: a multicenter study. Journal Of Neurosurgery 2014, 120: 1268-77. PMID: 24678777, DOI: 10.3171/2014.2.jns13139.Peer-Reviewed Original ResearchConceptsGamma knife radiosurgeryPrior radiation therapyParasellar meningiomasSellar meningiomasKnife radiosurgeryRadiation therapyPrior surgeryMulticenter studyTumor controlTumor volumeActuarial progression-free survival ratesNorth American Gamma Knife ConsortiumTumor progressionProgression-free survival ratesCox multivariate regression analysisTumor margin doseNew neurological deficitsCranial nerve deficitsPrimary treatment modalityKaplan-Meier analysisCranial nerves VLarger tumor volumeConventional radiation therapyMonths of imagingMultivariate regression analysisDelayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors
Wang C, Roberts KB, Bindra RS, Chiang VL, Yu JB. Delayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors. Pediatric Neurology 2014, 50: 549-556. PMID: 24739378, DOI: 10.1016/j.pediatrneurol.2013.09.018.Peer-Reviewed Original ResearchConceptsMedian interval periodIntracerebral hemorrhageMoyamoya syndromeInterval periodCranial radiation therapyRadiation doseIntracerebral hemorrhage casesMoyamoya casesCerebral vasculopathyCerebrovascular injuryMedian agePatient agePediatric patientsDoses of radiationDisease presentationPediatric tumorsRadiation therapyHemorrhage casesHemorrhagePatientsCerebrovasculopathySignificant associationMoyamoyaSyndromeTime of radiation
2013
Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study.
Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, Lee JY, Kano H, Park KJ, Niranjan A, Kondziolka D, Barnett GH, Rush S, Golfinos JG, Lunsford LD. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. Journal Of Neurosurgery 2013, 119: 446-56. PMID: 23621595, DOI: 10.3171/2013.3.jns12766.Peer-Reviewed Original ResearchConceptsPrior radiation therapyPituitary adenomasTumor controlNonfunctional pituitary adenomasNerve dysfunctionRadiation therapyNorth American Gamma Knife ConsortiumActuarial tumor controlDegree of hypopituitarismMulticenter patient populationTime of radiosurgeryCranial nerve deficitsPercent of patientsCranial nerve functionOptic nerve dysfunctionCranial nerve dysfunctionGamma Knife surgeryManagement of patientsOverall tumor controlGamma knife radiosurgeryExternal beam radiotherapyProgressive cranial nerve deficitsCommon intracranial neoplasmsDelayed hypopituitarismMargin dosesRole of stereotactic radiosurgery in patients with more than four brain metastases
Jairam V, Chiang V, Yu JB, Knisely J. Role of stereotactic radiosurgery in patients with more than four brain metastases. CNS Oncology 2013, 2: 181-193. PMID: 24273642, PMCID: PMC3835313, DOI: 10.2217/cns.13.4.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyBrain metastasesStereotactic radiosurgeryIntracranial relapseUse of SRSFirst-line therapyFirst-line treatmentNeurocognitive side effectsTreatment of patientsMultiple small dosesUndetected metastasesMedical CenterRadiation therapyHigh doseInstitutional trialsSide effectsPatientsMetastasisWhole brainSmall dosesTarget volumeEarly dementiaMemory lossRadiation treatmentRelapse
2011
Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update
Park HS, Chiang VL, Knisely JP, Raldow AC, Yu JB. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. Expert Review Of Anticancer Therapy 2011, 11: 1731-1738. PMID: 22050022, DOI: 10.1586/era.11.165.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyStereotactic radiosurgeryBrain metastasesAddition of SRSUse of SRSMD Anderson Cancer CenterWhole brain radiotherapyLocal tumor controlStandard of careAnderson Cancer CenterNormal brain tissueNonrandomized evidenceLimited metastasesOligometastatic diseaseCancer CenterTumor controlRelative sparingRadiation therapyBrain tissueMetastasisSingle fractionNormal tissuesPatientsRadiosurgeryTrialsDelayed Radiation-Induced Vasculitic Leukoencephalopathy
Rauch PJ, Park HS, Knisely JP, Chiang VL, Vortmeyer AO. Delayed Radiation-Induced Vasculitic Leukoencephalopathy. International Journal Of Radiation Oncology • Biology • Physics 2011, 83: 369-375. PMID: 22024206, DOI: 10.1016/j.ijrobp.2011.06.1982.Peer-Reviewed Original ResearchConceptsGamma knife radiosurgeryKnife radiosurgeryRadiation therapyYale-New Haven HospitalRadiation-induced leukoencephalopathyHigh-dose radiation fieldT cell infiltrationMetastatic brain cancerFocused radiation therapyMedium-sized vesselsNew Haven HospitalActive vasculitisLeukoencephalopathic changesVasculitic componentBrain metastasesVascular sclerosisNeuropathologic examinationSignificant morbiditySurgical managementTumor recurrencePathological evidenceHistopathologic observationsLeukoencephalopathyPathological differencesBrain cancer
2010
Biochemical and clinical responses after treatment of a catecholamine‐secreting glomus jugulare tumor with gamma knife radiosurgery
Castrucci WA, Chiang VL, Hulinsky I, Knisely JP. Biochemical and clinical responses after treatment of a catecholamine‐secreting glomus jugulare tumor with gamma knife radiosurgery. Head & Neck 2010, 32: 1720-1727. PMID: 19787788, DOI: 10.1002/hed.21242.Peer-Reviewed Original ResearchConceptsGlomus jugulare tumorsGamma knife radiosurgeryJugulare tumorsKnife radiosurgeryFunctional capacitySingle-fraction gamma knife radiosurgeryTumor growthMinimal treatment-related morbidityPrimary radiation therapyTreatment-related morbiditySignificant symptomatic improvementLocal tumor growthCatecholamine blockadeHypertensive crisisSymptomatic improvementClinical responseCatecholamine levelsPharmacologic blockadeRadiation therapyDurable controlRadiosurgeryBlockadeTumorsTreatmentMorbidity